NAS:SNY (France)
Business Description
Sanofi SA
NAICS : 325412
SIC : 2834
54, Rue La Boetie, Paris, FRA, 75008
Compare
Compare
Traded in other countries / regions
SANO.Austria
•
SAN.France
•
SNW.Germany
•
SANF.Italy
•
SNY.Mexico
•
SAN.Switzerland
•
0O59.UK
•
SNY.USA
Description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.33 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | 2.47 | |||||
| Interest Coverage | 26.81 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.07 | |||||
| Beneish M-Score | -2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.1 | |||||
| 3-Year EBITDA Growth Rate | 2.4 | |||||
| 3-Year EPS without NRI Growth Rate | 12.9 | |||||
| 3-Year FCF Growth Rate | 1.5 | |||||
| 3-Year Book Growth Rate | 5.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 6.37 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 4.63 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.51 | |||||
| 9-Day RSI | 48.32 | |||||
| 14-Day RSI | 46.77 | |||||
| 6-1 Month Momentum % | -3.65 | |||||
| 12-1 Month Momentum % | -0.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.31 | |||||
| Days Inventory | 259.02 | |||||
| Days Sales Outstanding | 64.36 | |||||
| Days Payable | 171.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.51 | |||||
| Dividend Payout Ratio | 0.63 | |||||
| 3-Year Dividend Growth Rate | 1.8 | |||||
| Forward Dividend Yield % | 3.51 | |||||
| 5-Year Yield-on-Cost % | 3.86 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.45 | |||||
| Operating Margin % | 23.53 | |||||
| Net Margin % | 15.8 | |||||
| ROE % | 9.82 | |||||
| ROA % | 5.62 | |||||
| ROIC % | 7.98 | |||||
| ROC (Joel Greenblatt) % | 63.68 | |||||
| ROCE % | 8.64 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.43 | |||||
| Forward PE Ratio | 12.2 | |||||
| PE Ratio without NRI | 18.43 | |||||
| Shiller PE Ratio | 21.29 | |||||
| Price-to-Owner-Earnings | 17.82 | |||||
| PEG Ratio | 2.88 | |||||
| PS Ratio | 2.91 | |||||
| PB Ratio | 1.72 | |||||
| EV-to-EBIT | 16.21 | |||||
| EV-to-Forward-EBIT | 12.06 | |||||
| EV-to-EBITDA | 15.87 | |||||
| EV-to-Forward-EBITDA | 10.08 | |||||
| EV-to-Revenue | 3.24 | |||||
| EV-to-Forward-Revenue | 3.18 | |||||
| EV-to-FCF | -72.02 | |||||
| Price-to-Projected-FCF | 1.17 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.1 | |||||
| Earnings Yield (Greenblatt) % | 6.17 | |||||
| Forward Rate of Return (Yacktman) % | 10.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:SNY
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 45,986.549 | ||
| EPS (TTM) ($) | 2.896 | ||
| Beta | 0.52 | ||
| Volatility % | 15.6 | ||
| 14-Day RSI | 46.77 | ||
| 14-Day ATR ($) | 0.952662 | ||
| 20-Day SMA ($) | 49.9635 | ||
| 12-1 Month Momentum % | -0.75 | ||
| 52-Week Range ($) | 46.925 - 58.1 | ||
| Shares Outstanding (Mil) | 2,500.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanofi SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||